Clinical trial · Interventional
Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.
A Phase II Evaluation of Oral Enzastaurin HCl in Second-and Third- Line Treatment of Patients With Non-Small Cell Lung Cancer
NCT00105092CI-TRIAL-00000710completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Enzastaurin given daily to patients with non-small cell lung cancer who have failed at least one prior therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small-Cell Lung Carcinoma | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Enzastaurin HCL | Drug | Enzastaurin | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To estimate the rate of progression-free survival at 6 months for patients receiving oral enzastaurin with NSCLC who are eligible for second-or third-line therapy
Secondary outcomes (8)
- measure
- To evaluate the pharmacokinetics of enzastaurin using sparse sampling methodology in this population
- measure
- To assess the QTc interval at anticipated steady state levels of enzastaurin (centrally collected 12-lead ECG on Day 1 of Cycle 2)
- measure
- To estimate the objective response rate (complete response [CR] and partial response [PR])
- measure
- To estimate time-to-event variables, such as overall survival time, duration of overall response (up to 1 year), and duration of stable disease (up to 1 year)
- measure
- To evaluate the safety of enzastaurin in this patient population
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Must be at least 18 years old * Must have been diagnosed with advanced or metastatic non-small cell lung cancer * Must be able to visit the doctor's office every 28 days for 6 months or longer. Exclusion Criteria: * Pregnant or breastfeeding women * Have other significant medical problems as determined by your physician * Are unable to swallow tablets * Have a history of significant heart disease
References
Publications (0)
Data not yet available
No reference posted for this study.